Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAX long-term extension study of mirikizumab in Crohn's disease
MOH_2021-01-11_009657Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of mirikizumab in Crohn's disease and inflammatory bowel disease (IBD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Maintenance of endoscopic response. Started Jan 2021; status: active, not recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on MOH_2021-01-11_009657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-11_009657.